Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.20.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Revenues        
Royalty $ 1,872 $ 0 $ 2,112 $ 0
Product 3,322 0 3,626 0
Total Revenues 5,194 0 5,738 0
Operating Expenses        
Research and development 3,492,845 2,478,930 7,387,811 4,953,489
General and administrative 1,508,836 1,436,461 3,212,358 2,665,901
Sales and marketing 215,891 238,124 489,845 522,404
Total Operating Expenses 5,217,572 4,153,515 11,090,014 8,141,794
Operating Loss (5,212,378) (4,153,515) (11,084,276) (8,141,794)
Other Income (Expenses)        
Grant income 90,946 0 98,870 0
Gain on disposal of fixed assets 93,202 0 93,202 0
Interest income 7,741 29,459 46,155 41,023
Interest expense (22,604) (33,115) (56,383) (63,216)
Other expenses 0 0 0 (196,957)
Total Other Income (Expenses) 169,285 (3,656) 181,844 (219,150)
Provision for Income Taxes 0 0 0 0
Net Loss (5,043,093) (4,157,171) (10,902,432) (8,360,944)
Net Loss attributable to Non-Controlling Interest 5,779 0 15,346 0
Net Loss attributable to VolitionRx Limited Stockholders (5,037,314) (4,157,171) (10,887,086) (8,360,944)
Other Comprehensive Income (Loss)        
Foreign currency translation adjustments (74,320) 49,913 299,606 25,859
Net Comprehensive Loss $ (5,117,413) $ (4,107,258) $ (10,602,826) $ (8,335,085)
Net Loss Per Share - Basic and Diluted attributable to VolitionRx Limited $ (0.12) $ (0.11) $ (0.26) $ (0.22)
Weighted Average Shares Outstanding        
Basic and Diluted 43,414,318 38,876,262 42,312,172 37,266,356